Ongoing LDN Research Projects

Visit our LDN Fellowship page to learn about the LDN Fellowship program!

Metachromatic Leukodystrophy Study Is Enrolling Participants

Dr. Laura Adang, 2017-2018 LDN Fellow, is excited to announce the launch of a multi-center natural history study of metachromatic leukodystrophy (MLD) in collaboration with her mentor Dr. Adeline Vanderver of the Children’s Hospital of Philadelphia and the Global Leukodystrophy Initiative. Sponsors and collaborators include the Lysosomal Disease Network, Children’s Hospital of Philadelphia, National Institutes of Health and Massachusetts General Hospital. Individual physicians may contribute to the success of this research by enrolling one or more metachromatic leukodystrophy participants.  More information is available on for study NCT03047369.

Collaborators will also be remunerated on a per-patient basis for data contributed to the study. To refer a patient, or to learn more about participating in this study, please e-mail study coordinator Omar Sherbini or phone (215) 590-3068.

Call for Participants to Enroll In
the LDN’s Gaucher Disease Research Study
That Uses a Nutritional Supplement

Study Locations: University of Minnesota in the Twin Cities;
and New York University in New York City

The search is on for Gaucher disease patients who fit the eligibility criteria for the Lysosomal Disease Network’s ongoing research study entitled “Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1): Potential Use of Antioxidant/Anti-inflammatory Medications.” (The Rare Diseases Clinical Research Network will make every effort to enroll all the patients it can, but it cannot make any guarantees that it will be able to enroll everyone in a particular study who wants to participate.) Many details about this study can be found at under its study number NCT02583672.

Drug Development is Important
Briefly, the purpose of this study is to measure blood and brain chemicals related to oxidative stress and inflammation in healthy volunteers and individuals with type 1 Gaucher disease (“GD1”). The investigators want to learn if these levels are abnormal in patients with GD1. They will also examine if there is a change in these blood and brain chemicals in GD1 patients after treatment with orally-administered N-acetylcysteine (NAC). NAC is available both as a prescription medication and as a “natural supplement” product in some retail markets. NAC has antioxidant and anti-inflammatory effects, and has been used for many years for the treatment of lung diseases, such as chronic obstructive pulmonary disease, and cystic fibrosis. The findings from this study may add to our understanding of how Gaucher disease causes tissue damage, and may lead to better treatment options for GD1.

The principal investigators of this study are James C. Cloyd III, PharmD, and Reena Kartha, PhD, located at the University of Minnesota in the Twin Cities. To see if you may be eligible to participate, first read the entry at, and after that, you may e-mail your questions to Dr. Kartha at the University of Minnesota. Thank you for your time and consideration!